[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371299-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371299-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","claudin-182-is-not-a-promising-biomarker-for-targeted-immunotherapy-in-prostatic-cancers","Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers","","Claudin 18.2 (CLDN18.2) is a highly selective biomarker and has been proposed as a prognostic indicator and therapeutic target in several malignancies. This study evaluates CLDN18.2 expression in 168 prostate cancer tissue samples, examining associations with clinicopathological factors and its potential for anti-CLDN18.2 immunotherapy. Immunohistochemistry used an approved CLDN18.2 protocol with Ventana 43-14A clone. Results show strong membranous staining in positive control gastric mucosa, but no CLDN18.2 expression in prostate normal ducts/acini or any tumor specimens.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/claudin-182-is-not-a-promising-biomarker-for-targeted-immunotherapy-in-prostatic-cancers/371299/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/claudin-182-is-not-a-promising-biomarker-for-targeted-immunotherapy-in-prostatic-cancers/371299.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of this study on CLDN18.2 in prostate cancer?","Question",{"text":63,"@type":64},"To assess CLDN18.2 expression in 168 prostate cancer tissues, analyze correlations with clinicopathological factors, and evaluate whether it could serve as a therapeutic target for anti-CLDN18.2 immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CLDN18.2 expression measured?",{"text":68,"@type":64},"Through immunohistochemical staining using an approved diagnostic CLDN18.2 protocol with the Ventana 43-14A clone and interpretation following general staining evaluation rules.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding CLDN18.2 expression in prostate tissues?",{"text":72,"@type":64},"Strong membranous staining was observed in non-neoplastic gastric mucosa as a positive control, while CLDN18.2 was not detected in normal prostate ductal/acinar cells or in any of the 168 variable prostate cancer tissues.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371299,1790816218,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","doi: 10.21873/invivo.13884  \nClaudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers  \nJINA BAEK1, YOUNG RAN SHIM2 and MI‐JIN GU3  \n1 Department of Pathology, Samkwang Medical Lab, Seoul, Republic of Korea;  \n2 Department of Pathology, Yeungnam University Yeongcheon Hospital, Yeongcheon, Republic of Korea; 3 Department of Pathology, Yeungnam University College of Medicine, Daegu, Republic of Korea  \nAbstract  \nBackground/Aim: Claudin 18.2 (CLDN18.2) has emerged as a highly selective biomarker and its abnormal expression has been reported in various primary malignant tumors. Recently, CLDN18.2 has gained attention asboth a prognostic biomarker and a potential therapeutic target in gastric and gastroesophageal junction cancer. The purpose of this study was to investigate CLDN18.2 expression in a large cohort of 168 prostate cancer (PC) tissues, assess its correlation with clinicopathological factors, and evaluate its potential as a therapeutic target for anti‑CLDN18.2 therapy. Materials and Methods: Immunohistochemical staining was conducted using an approved diagnostic CLDN18.2 immunohistochemistry protocol (Ventana, 43‑14A clone). Interpretation was carried out following the general rules for staining evaluation.  \nResults: Non‑neoplastic gastric mucosa, used as a positive control for CLDN18.2 immunostaining, exhibited strong membranous staining. In contrast, no CLDN18.2 expression was detected in normal ductal and acinar cells of prostate tissue, nor in any of the 168 variable PC tissues.  \nConclusion: CLDN18.2 is not expressed in normal prostate tissue or PC, suggesting that it is unlikely to serve as a prognostic marker or a potential target for immunotherapy in PC.  \nKeywords: Biomarker, Claudin 18.2, therapeutic target, prostate cancer.  \nIntroduction  \nProstate cancer (PC) is the second most frequent cancer diagnosis made in men and the fifth leading cause of death  \nworldwide (1). The heterogeneous nature of PC complicates its diagnosis, prognosis, and treatment. Numerous biomarkers have been explored for predictive, diagnostic, prognostic, and risk assessment purposes through various  \n✉  \nProfessor Mi Jin Gu, Department of Pathology, Yeungnam University College of Medicine, 170, Hyeonchung‑ro, Nam‑gu, Daegu 42415, Republic of Korea. Tel: +82 56406756, e‑[mail: mjgu@yu.ac.kr](mail: mjgu@yu.ac.kr)  \nReceived December 24, 2024 | Revised January 7, 2025 | Accepted January 8, 2025  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2025 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \npopulation studies. However, to date, no promising biomarker has been universally approved or validated for PC (2). Prostate‑specific antigen (PSA) remains the standard biomarker for PC detection and screening, but its limited specificity and sensitivity reduce its diagnostic accuracy (3). Moreover, despite advancementsin treatment modalities for PC, more than 30% of patients may eventually have their PC progress and metastasize/relapse and ultimately leading to fatal outcomes (4).  \nClaudins are integral membrane proteins that form tight junctions between cells, playing a crucial role in regulating paracellular transport and maintaining epithelial integrity (5) . Among them, Claudin 18.2 (CLDN18.2) has emerged as a highly selective biomarker with limited expression in normal tissues and is involved in the proliferation, differentiation, and migration of tumor cells (6) . Abnormal expression of CLDN18.2 has been reported in various primary malignant tumors, including gastric/gastroesophageal junction, pancreatic, ovarian, and non‑small‑cell lung cancer (6‑9). Recently, CLDN18.2 has garnered attention as a potential therapeutic target in gastric and gastroesophageal junction cancers, with promising res","cbCaigJenGOWXuNr","https://ap.wps.com/l/cbCaigJenGOWXuNr","pdf",1525132,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Study samples\n## Immunohistochemistry with tissue microarray block\n# Results\n## CLDN18.2 expression\n# Conclusion","[{\"question\":\"What was the main purpose of this study on CLDN18.2 in prostate cancer?\",\"answer\":\"To assess CLDN18.2 expression in 168 prostate cancer tissues, analyze correlations with clinicopathological factors, and evaluate whether it could serve as a therapeutic target for anti-CLDN18.2 immunotherapy.\"},{\"question\":\"How was CLDN18.2 expression measured?\",\"answer\":\"Through immunohistochemical staining using an approved diagnostic CLDN18.2 protocol with the Ventana 43-14A clone and interpretation following general staining evaluation rules.\"},{\"question\":\"What were the key findings regarding CLDN18.2 expression in prostate tissues?\",\"answer\":\"Strong membranous staining was observed in non-neoplastic gastric mucosa as a positive control, while CLDN18.2 was not detected in normal prostate ductal/acinar cells or in any of the 168 variable prostate cancer tissues.\"}]","Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers | PDF",1790191736,13,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86fa104965a0b09d0390b971446261b1.webp",983,1301,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de40ef8f47a1dc18ca886ead42460810.webp",982,1299,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b87b2fc6bb6ae75a482a54806640ad27.webp",981,1298,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95a4ba1e807a8f9bc9736fdbc086a51d.webp",980,1297]